Holen Sie sich die Stockscreener-App
177.80
1.75%
3.05
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Natera CEO Steve Chapman: Treatment on Molecular Recurrence Will Reshape Oncology in 5 Years - finance.biggo.com
Guardant Health, Inc. (GH) stock price, news, quote and history - uk.finance.yahoo.com
Asset turnover of Guardant Health, Inc. – HAN:5GH - TradingView
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
Could Guardant Health (NASDAQ:GH) Reset Its Market Story? - Kalkine Media
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo! Finance Canada
This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval - marketwatch.com
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com Canada
Guardant Health (GH) director adds 264 shares from RSU vesting - Stock Titan
Guardant Health Inc (GH) Shares Fall 3.1% -- What GF Score of 65 Tells Investors - gurufocus.com
Tempus AI Fails to Trim Guardant Lawsuit Over Diagnostic Tests - news.bloomberglaw.com
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $225 - moomoo.com
Guardant Health, Inc. (GH) Stock Analysis: A Strong Buy With 9% Upside Potential - DirectorsTalk Interviews
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening - The National Law Review
Guardant Health Director Steve E. Krognes Sells 6,674 Shares Between $174.46 and $177.48 - Kalkine Media
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role - Yahoo Finance
Director Steve Krognes Sells 6,674 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health on Track for Record High Close -- Data Talk - Bitget
Cathie Wood’s ARK increases stake in Guardant Health stock - Investing.com
Guardant Health (GH) director plans new stock sale - Stock Titan
Guardant Health (NASDAQ: GH) director may sell $144K in equity-comp stock - stocktitan.net
Guardant Health (NASDAQ: GH) director moves to sell 6,674 shares - Stock Titan
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH) - Yahoo Finance
Cathie Wood’s ARK buys Guardant Health stock, sells Iridium - Investing.com
Officer at Guardant Health (NASDAQ: GH) plans sale of 7,738 shares under Rule 144 - Stock Titan
Guardant Health stock hits 52-week high at 176.68 USD - Investing.com
Guardant Health (GH) Insider Sale: Chief Information Officer Kum - GuruFocus
Guardant Health CIO Kumud Kalia sells $632k in stock - Investing.com
Is Guardant Health Inc (GH) Overvalued After 6.6% Rally? GF Valu - GuruFocus
Guardant Health rises as investors weigh recent FDA approval, coverage expansion, and supportive analyst views - Quiver Quantitative
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening - FinancialContent
Guardant Health, Inc. (GH) Stock Analysis: 24% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Inc Share PriceGH, RNS News, Articles, Quotes, & Charts - Proactive financial news
Guardant Health (NASDAQ: GH) officer moves to sell more stock - stocktitan.net
(GH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - BioSpace
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating - investing.com
Rothschild & Co Redburn Initiates Guardant Health at Buy - Yahoo Finance
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - morningstar.com
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
GH Looks 144.6% Overvalued on GF Value™ - GuruFocus
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection - Yahoo Finance
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer - Yahoo Finance
AstraZeneca Breast Cancer Drug Etcamah Nets Accelerated FDA Approval With Guardant Health ctDNA Test - GenomeWeb
AmirAli Talasaz Reflects on Lives Lost to Colorectal Cancer – Guardant Health - Oncodaily
A Look at Guardant Health Inc (GH) After 3.4% Gain -- GF Value $65.83 vs Price $164.41 - GuruFocus
Guardant Health rises as investors weigh strong growth outlook against patent overhang - Quiver Quantitative
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):